-estrant
Drugs that block oestrogen receptors, some also degrading them.
- Drugs ending in -estrant: 13
- Approved somewhere: 2
- With a US drug page: 6
- Stem
- -estrant
- Class
- Drugs that block oestrogen receptors, some also degrading them
- Most common targets
- ESR1 (6)
Approved and clinical-stage drugs in ChEMBL whose names ending in -estrant, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Elacestrant | Approved | ESR1 | Estrogen receptor alpha degrader |
| Fulvestrant | Approved | ESR1 | Estrogen receptor alpha antagonist |
| Camizestrant | Phase 3 | ESR1 | Estrogen receptor alpha degrader |
| Imlunestrant | Phase 3 | — | — |
| Vepdegestrant | Phase 3 | — | — |
| Imlunestrant tosylate | Phase 1 | — | — |
| Amcenestrant | Phase 3 | ESR1 | Estrogen receptor alpha degrader |
| Giredestrant | Phase 3 | ESR1 | Estrogen receptor alpha degrader |
| Bexirestrant | Phase 2 | — | — |
| Brilanestrant | Phase 2 | ESR1 | Estrogen receptor degrader |
| Palazestrant | Phase 2 | — | — |
| Taragarestrant | Phase 2 | — | — |
| Rintodestrant | Phase 1 | — | — |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO